COLLECTED BY
Collection:Wikipedia Eventstream
TIMESTAMPS
| 2019 | |
 | Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%read more... |
| 2018 | |
| Akorn Receives FDA Approval for Diclofenac Sodium Topical Gel, 1%read more... |
| Akorn Receives FDA Approval for Clobetasol Propionate Lotion, 0.05%read more... |
| Akorn Receives FDA Approval for Bimatoprost Ophthalmic Solution, 0.03%read more... |
| 2017 | |
| Akorn Receives FDA Approval for Mycophenolate Mofetil for Injection, USPread more... |
| 2015 | |
| Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solutionread more... |
| 2014 | |
| Akorn Acquires Xopenex® (levalbuterol HCI) Inhalation Solutionread more... |
| Akorn Acquires Hi-Tech Pharmacal.read more... |
| Akorn Acquires VersaPharm.read more... |
| 2013-2014 | |
| Akorn Acquires Four Branded Ophthalmic Products: Zioptan®, CosoptPF/Cosopt®, AzaSite®, and Betimol®. |
| 2012 | |
| Generic Vancocin® is approved and launched. |
| 2011 | |
| Advanced Consumer Health is acquired to expand presence in a $1.2 billion over-the-counter eye care market.read more... |
| A Minority Stake inAciex Therapeutics is acquired providing access to an innovative ophthalmic pipeline.read more... |
| Entered into agreement to acquire assets fromKilitch Drugs of India to expand manufacturing of sterile injectables and global reach.read more... |
| Nembutal®, a Schedule II controlled drug, Diuril® and Cogentin® are acquired from Lundbeck Pharma. |
| 2010 | |
| TheAkorn R&D Center in Skokie, IL is opened to provide leading edge capabilities for the development of new and generic pharmaceuticals. |
| 2008 | |
| Corporate Headquarters are moved toLake Forest, Illinois. |
| Warehousing is relocated toGurnee, Illinois. |
| Akten® (lidocaine HCI ophthalmic gel) 3.5%, Akorn's first internally developed NDA indicated for topical ocular anesthesia is launched. |
| 2007 | |
| Akorn, Inc. is listed on theNASDAQ exchange. |
| 2004 | |
| Akorn Inc. andStrides Arcolab Ltd. enter into a joint venture asAkorn-Strides, LLC. |
| 2002 | |
| Paremyd® (hydroxyamphetamine hydrobromide and tropicamide, ophthalmic solution), a convenient one-drop dilation agent is launched. |
| 1998 | |
| Advanced Remedies Incorporated is acquired inSomerset, New Jersey, a division of Sidmak laboratories and manufacturer of sterile ophthalic ointments and solutions. |
| 1997 | |
| Akorn Inc. is founded. Corporate headquarters and distribution offices are moved toBuffalo Grove, Illinois. |
| Indocyanine green, nowIC-Green®, Akorn's first New Drug Application (NDA) ophthalmic drug for retina diagnostic imaging, is acquired from Becton Dickinson (BD). |
| 1996 | |
| Taylor Pharmacal Company begins operating under the name ofAkorn Manufacturing. |
| Pasadena Research Laboratories in Pasadena, California is acquired along with its injectable line of products. |
| 1994 | |
| TheGrand facility in Decatur is expanded to add ophthalmic filling operations. |
| 1992 | |
| The Taylor family sells Taylor Pharmacal Company toAkorn Inc., a Louisiana based ophthalmic sales and distribution company, that owns ophthalmic products under theAkorn Ophthalmics label. |
| 1977 | |
| TheWyckles facility in Decatur, Illinois is constructed to provide packaging and warehouse operation and to allow expansion of the filling and laboratory testing areas at the Grand facility. |
| 1971 | |
| Akorn Ophthalmics is founded in Abita Springs, Louisiana |
| 1953 | |
| TheGrand facility in Decatur, Illinois is constructed to provide a filling and packaging location for the manufacture of pharmaceutical products. |
| 1948 | |
| Taylor Pharmacal is founded by Guy Taylor and his two sons in Decatur Illinois. |
Advancing The New Vision
© Copyright 2019 Akorn, Incorporated All Rights Reserved | 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045 | 800.932.5676